Jann, Michael W.

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics

Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatments

Cited by 365

Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective

Desai, H. D., Seabolt, J., & Jann, M. W. (2001) · CNS Drugs

Pharmacogenetics and Drug MetabolismSmoking Behavior and Cessation

Cited by 253

Antidepressant Agents for the Treatment of Chronic Pain and Depression

Jann, M. W., & Slade, J. H. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Treatment of Major DepressionPain Mechanisms and Treatments

Cited by 172

Clinical Pharmacokinetics of the Depot Antipsychotics

Jann, M. W., Ereshefsky, L., & Saklad, S. R. (1985) · Clinical Pharmacokinetics

Schizophrenia research and treatmentPharmacogenetics and Drug Metabolism

Cited by 125

Clinically Significant Drug Interactions with Atypical Antipsychotics

Kennedy, W. K., Jann, M. W., & Kutscher, E. C. (2013) · CNS Drugs

Pharmacogenetics and Drug MetabolismSchizophrenia research and treatment

Cited by 95

Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: A narrative review

Yuet, W. C., Ebert, D., & Jann, M. (2021) · Therapeutic Advances in Drug Safety

Lipoproteins and Cardiovascular HealthAlzheimer's disease research and treatments

Cited by 8